2019 American Transplant Congress
Protocol Cidofovir for Refractory Polyomavirus Associated Nephropathy in Kidney Transplant Recipients
University of Maryland Medical Center, Baltimore, MD
*Purpose: Dose-limiting nephrotoxicity has historically precluded the use of cidofovir for polyomavirus associated nephropathy (PVAN). With incidence of BK viremia in kidney transplant recipients increasing…2018 American Transplant Congress
Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients and Role of Prophylaxis
Objectives: Cytomegalovirus (CMV) is an opportunistic infection that can lead to significant complications post-transplant. Purpose of this study was to evaluate the use of valganciclovir…2018 American Transplant Congress
Val-Ganciclovir Prophylaxis Delays Onset of EBV Viremia in the First Year Post-Solid Organ Transplantation in High-Risk Patients
1University of British Columbia, Vancouver, Canada; 2University of Manitoba, Winnipeg, Canada.
Introduction: Donor-derived primary Epstein-Barr virus (EBV) infection poses serious risks to EBV naïve children post-solid organ transplantation, including development of EBV-related PTLD. Currently, there is…2018 American Transplant Congress
Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Genotype 4 HCV is the most common genotype in Saudi Arabia and the Middle East. Management of genotype 4 HCV has shifted to interferon free…2018 American Transplant Congress
Effect of Direct-Acting Hepatitis C Treatment Regimens on Calcineurin Inhibitors in Liver and Kidney Transplant Patients
Duke University Hospital, Durham, NC.
Background: It has been suggested that treatment with direct-acting antivirals (DAA) for hepatitis C virus (HCV) may decrease calcineurin inhibitor (CNI) concentrations. The purpose of…2018 American Transplant Congress
Building a Third-Party VST Bank from Scratch- The Cincinnati Experience
BackgroundViral infections remain a challenge to treat and significantly contribute to morbidity and mortality. Virus specific T cells (VSTs) have shown clinical efficacy, with minimal…2018 American Transplant Congress
Prospective, Multi-Center Observational Study of Cell-Mediated Immunity for Cytomegalovirus Infection in Kidney Transplant Recipients
Background:T-cell-mediated immunity (CMI) is crucial for the control of CMV infection post-transplant. We evaluated a novel EliSpot assay to determine whether CMI results could predict…2018 American Transplant Congress
Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant
Michigan Medicine, Ann Arbor, MI.
Background: Direct acting antivirals (DAA) have transformed hepatitis C virus (HCV) management post-liver transplant (LT). As HCV clears, hepatic metabolism improves, resulting in decreased tacrolimus…2018 American Transplant Congress
Direct-Acting Antiviral Therapy Immune-Mediated Graft Dysfunction in Liver Transplant Recipients with Hepatitis C
Background and Aims:Interferon (IFN) treatment of hepatitis C virus (HCV) infection after liver transplantation (LT) can result in severe immune-mediated graft dysfunction (IGD). The occurrence…2018 American Transplant Congress
Incidence of Acute Cellular Rejection in Liver Transplant Patients Receiving Direct Acting Antivirals for Hepatitis C Treatment
Direct acting antivirals (DAAs) have been used for the treatment of hepatitis C (HCV) in liver transplant patients since early on after their approval, however…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 14
- Next Page »